Diagnosis and Management of Infantile Hemangioma

KQ2. Among newborns, infants, and children up to 18 years of age with
infantile hemangiomas who have been referred for pharmacologic
intervention, what is the comparative effectiveness (benefits/harms) of
corticosteroids or beta-blockers?
KQ3. Among newborns, infants, and children up to 18 years of age with
infantile hemangiomas for whom treatment with corticosteroids or betablockers
is unsuccessful what is the comparative effectiveness of second
line therapies including immunomodulators and angiotensin-converting
enzyme inhibitors?
KQ4. Among newborns, infants, and children up to 18 years of age with
infantile hemangiomas who have been referred for surgical intervention,
what is the comparative effectiveness (benefits/ harms) of various types of
surgical interventions (including laser and resection)?
Analytic Framework
The analytic frameworks illustrate the population, interventions, and outcomes that guided
the literature search and synthesis (Figures 1-3). The frameworks depict the Key Questions
within the context of the population, intervention, comparator, outcomes, timing, and setting
(PICOTS) parameters described in the review. In general, the figures illustrate how imaging
modalities or interventions such as magnetic resonance imaging (MRI), beta-blockers, or laser
may result in intermediate outcomes such as change in hemangioma size or change in vision
and/or in final health outcomes such as detection of IH for imaging modalities or resolution of
hemangioma or changes in quality of life for medical or surgical treatments. Also, adverse events
may occur at any point after the intervention is received.
Figure 1. Analytic framework for KQ1
IH = infantile hemangioma; KQ = Key Question
4